Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 4—April 2020
Dispatch

Rift Valley Fever Outbreak, Mayotte, France, 2018–2019

Hassani YoussoufComments to Author , Marion Subiros, Genevieve Dennetiere, Louis Collet, Laure Dommergues, Amandine Pauvert, Patrick Rabarison, Christelle Vauloup-Fellous, Gilles Le Godais, Marie-Christine Jaffar-Bandjee, Maxime Jean, Marie-Claire Paty, Harold Noel, Sophie Oliver, Laurent Filleul, and Christine Larsen
Author affiliations: Santé Publique France, Mayotte, France (H. Youssouf, M. Subiros, C. Larsen); Agence Régionale de Santé Océan Indien, Mayotte (G. Dennetiere, P. Rabarison); Centre Hospitalier de Mayotte, Mayotte (L. Collet, C. Vauloup-Fellous, M. Jean, S. Olivier); Cooperative Agricole des Eleveurs Mahorais Coconi, Mayotte (L. Dommergues); Direction de l’Alimentation, de l’Agriculture, et de la Foret de Mayotte, Mayotte (A. Pauvert, G. Le Godais); Université Paris-Sud, INSERM U1193, Villejuif, France (G. Le Godais); CNR associé des arboviruses, CHU Réunion, CH Félix Guyon, Saint-Denis, La Réunion, France (M. Jaffar-Bandjee); Santé Publique France, Mayotte, France (M.-C. Paty, H. Noel, S. Olivier, L. Filleul)

Main Article

Table

Potential Rift Valley fever virus exposures and clinical signs for persons with Rift Valley fever, Mayotte, France, November 22–July 31, 2019

Variable No. (%) cases
Risk exposure, n = 142

Investigated 126 (88.7)
Direct contact with animals and their fluids, including milk 85 (67.5)
Living or working near livestock 19 (15.1)
No contact with animals or consumption of products at risk 22 (17.4)
Not investigated
16 (11.3)
Signs and symptoms reported by patients, n = 97
Fever 87 (89.7)
Arthralgia 61 (62.9)
Myalgia 42 (43.3)
Retroorbital pain 18 (18.6)
Headache 72 (74.2)
Weakness 49 (50.5)
Nausea/vomiting 31 (31.9)
Cough
5 (5.1)
Other signs and symptoms reported by doctors, n = 142
Meningitis 2 (1.4)
Meningoencephalitis 1 (0.7)
Meningeal syndrome 3 (2.1)
Neurologic signs 2 (1.4)
Ocular complication 1 (0.7)

Main Article

Page created: March 17, 2020
Page updated: March 17, 2020
Page reviewed: March 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external